Quantcast

Industry news that matters to you.  Learn more

Agendia Announces New Agreement with Daiichi Sankyo to Support Oncology Drug Development

Agendia recently announced a new agreement with Daiichi Sankyo regarding oncology drug development and personalized medicine. The agreement calls for Agendia’s oncology biomarker technology to be used in the assessment of novel pharmaceuticals now being researched in certain Daiichi Sankyo clinical trials.

Agendia Announces New Agreement with Daiichi Sankyo to Support Oncology Drug Development

Agendia recently announced a new agreement with Daiichi Sankyo regarding oncology drug development and personalized medicine. The agreement calls for Agendia’s oncology biomarker technology to be used in the assessment of novel pharmaceuticals now being researched in certain Daiichi Sankyo clinical trials.

Evotec Receives First Milestone in Roche Biomarker Collaboration

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) recently announced the successful achievement of a milestone in its biomarker alliance with Roche. The milestone was achieved on the decision by Roche to use a response prediction marker, identified using Evotec’s Proteome Profiling platform, in an extended phase I oncology trial.

Strand Genomics Inc. And BioHealth Innovation, Inc. Partner To Expand Strand Centers For Genomics & Personalized Medicine In The U.S.

Strand Genomics Inc. (Strand) and BioHealth Innovation, Inc. (BHI) recently announced a strategic partnership designed to expand the Strand Centers for Genomics & Personalized Medicine into the U.S. This effort is intended to help revolutionize access to genomic interpretation services in cardiovascular disease, oncology, rare diseases, and many other indications. Strand Genomics is a wholly owned subsidiary of Strand Life Sciences, a Bangalore, India-based bioinformatics, clinical genomics, and diagnostics company.

IntegraGen Collaborating with New EPOC Study Investigators to Validate Metastatic Colorectal Cancer Biomarker

IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, recently announced a collaboration with investigators from the New EPOC study to validate the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be a predictor of progression free survival in patients with metastatic colorectal cancer treated with anti-EGFR therapy.